{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:20:44Z","timestamp":1793395244152,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.cld.2021.07.001","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T19:20:45Z","timestamp":1632770445000},"page":"875-899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel Therapies That May Cure Chronic Hepatitis B Virus"],"prefix":"10.1016","volume":"25","author":[{"given":"Alessandro","family":"Loglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 Suppl","key":"10.1016\/j.cld.2021.07.001_bib1","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/hep.22881","article-title":"Hepatitis B: the virus and disease","volume":"49","author":"Liang","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2021.07.001_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.20517\/2394-5079.2016.05","article-title":"Hepatitis B virus molecular biology and pathogenesis","volume":"2","author":"Lamontagne","year":"2016","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.cld.2021.07.001_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0033-1345717","article-title":"The molecular virology of hepatitis B virus","volume":"33","author":"Glebe","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2021.07.001_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000024970","article-title":"Hepatitis B virus replication: novel roles for virus-host interactions","volume":"42","author":"Nassal","year":"1999","journal-title":"Intervirology"},{"key":"10.1016\/j.cld.2021.07.001_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.patbio.2010.03.005","article-title":"Molecular biology of the hepatitis B virus and role of the X gene","volume":"58","author":"Wei","year":"2010","journal-title":"Pathol Biol"},{"key":"10.1016\/j.cld.2021.07.001_bib6","first-page":"2923","article-title":"Hepadnaviridae: the viruses and their replication","volume":"2","author":"Ganem","year":"2001","journal-title":"Fields Virology"},{"key":"10.1016\/j.cld.2021.07.001_bib7","series-title":"Fields virology","first-page":"2971","article-title":"Hepatitis B virus","author":"Hollinger","year":"2001"},{"key":"10.1016\/j.cld.2021.07.001_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12072-017-9829-7","article-title":"Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread","volume":"11","author":"Karayiannis","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2021.07.001_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.meegid.2015.05.013","volume":"33","author":"Hao","year":"2015","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.cld.2021.07.001_bib10","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","article-title":"Overview of hepatitis B viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib11","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.3748\/wjg.v22.i31.7017","article-title":"Roles of hepatocyte nuclear factors in hepatitis B virus infection","volume":"22","author":"Kim","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2021.07.001_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2893.2002.00381.x","article-title":"Regulatory elements of hepatitis B virus transcription","volume":"9","author":"Moolla","year":"2002","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2021.07.001_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3748\/wjg.v20.i2.425","article-title":"Core promoter: a critical region where the hepatitis B virus makes decisions","volume":"20","author":"Quarleri","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2021.07.001_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: a pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cld.2021.07.001_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/fvl.14.113","article-title":"Unveiling the roles of HBV polymerase for new antiviral strategies","volume":"10","author":"Clark","year":"2015","journal-title":"Future Virol"},{"key":"10.1016\/j.cld.2021.07.001_bib16","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1038\/emi.2013.56","article-title":"Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention","volume":"2","author":"Jones","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.cld.2021.07.001_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.virusres.2007.12.024","article-title":"Hepatitis B viruses: reverse transcription a different way","volume":"134","author":"Nassal","year":"2008","journal-title":"Virus Res"},{"key":"10.1016\/j.cld.2021.07.001_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-virology-110615-042238","article-title":"The structural biology of hepatitis B virus: form and function","volume":"3","author":"Venkatakrishnan","year":"2016","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.cld.2021.07.001_bib19","doi-asserted-by":"crossref","first-page":"14913","DOI":"10.1073\/pnas.0406282101","article-title":"A\u00a0function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.cld.2021.07.001_bib20","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1073\/pnas.83.6.1578","article-title":"Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen","volume":"83","author":"Ou","year":"1986","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.cld.2021.07.001_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0042-6822(92)90764-G","article-title":"Preferential ribosomal scanning is involved in the differential synthesis of the hepatitis B viral surface antigens from subgenomic transcripts","volume":"188","author":"Sheu","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.cld.2021.07.001_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2893.2010.01315.x","article-title":"Control of hepatitis B virus at the level of transcription","volume":"17","author":"Quasdorff","year":"2010","journal-title":"J\u00a0Viral Hepat"},{"issue":"Suppl 3","key":"10.1016\/j.cld.2021.07.001_bib23","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0168-8278(05)80419-2","article-title":"Regulation of hepatitis B virus gene expression","volume":"17","author":"Huan","year":"1993","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib24","doi-asserted-by":"crossref","first-page":"36741","DOI":"10.1038\/srep36741","article-title":"LUC7L3\/CROP inhibits replication of hepatitis B virus via suppressing enhancer II\/basal core promoter activity","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cld.2021.07.001_bib25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.25522","article-title":"Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis","volume":"11","author":"Zhang","year":"2011","journal-title":"Hepat Mon"},{"key":"10.1016\/j.cld.2021.07.001_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.3961490","article-title":"Genetic and biochemical evidence for the hepatitis B virus replication strategy","volume":"232","author":"Seeger","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.cld.2021.07.001_bib27","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.cld.2021.07.001_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/v9050125","article-title":"A\u00a0role for the host DNA damage response in hepatitis B virus cccDNA formation\u2014and beyond?","volume":"9","author":"Schreiner","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.cld.2021.07.001_bib29","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure","volume":"64","author":"Zeisel","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cld.2021.07.001_bib30","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cld.2021.07.001_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.cld.2021.07.001_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(86)90602-1","article-title":"Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells","volume":"47","author":"Tuttleman","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.cld.2021.07.001_bib34","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","article-title":"Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones","volume":"130","author":"Pollicino","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2021.07.001_bib35","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/jvi.69.6.3350-3357.1995","article-title":"The covalently closed duplex form of the hepadnavirus genome exists in\u00a0situ as a heterogeneous population of viral minichromosomes","volume":"69","author":"Newbold","year":"1995","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2021.07.001_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2893.2007.00911.x","article-title":"Hepatocyte turnover in transient and chronic hepadnavirus infections","volume":"14","author":"Mason","year":"2007","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2021.07.001_bib37","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1128\/JVI.01587-08","article-title":"The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir","volume":"83","author":"Mason","year":"2009","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2021.07.001_bib38","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1172\/JCI118902","article-title":"Longlasting memory T\u00a0cell responses following self-limited acute hepatitis B","volume":"98","author":"Penna","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cld.2021.07.001_bib39","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","article-title":"The hepatitis B virus persists for decades after patients\u2019 recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response","volume":"2","author":"Rehermann","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.cld.2021.07.001_bib40","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jhep.2005.11.020","article-title":"Assessment of treatment efficacy in HBV infection and disease","volume":"44","author":"Zoulim","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib41","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1053\/j.gastro.2007.06.057","article-title":"Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients","volume":"133","author":"Volz","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2021.07.001_bib42","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1053\/j.gastro.2007.06.011","article-title":"Viral quasi-species evolution during hepatitis Be antigen seroconversion","volume":"133","author":"Lim","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2021.07.001_bib43","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","article-title":"Statements from the Taormina expert meeting on occult hepatitis B virus infection","volume":"49","author":"Raimondo","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib44","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib45","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib46","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2021.07.001_bib47","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cld.2021.07.001_bib48","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/acsinfecdis.8b00269","article-title":"Discovery of novel hepatitis B virus nucleocapsid assembly inhibitors","volume":"5","author":"Zhang","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.cld.2021.07.001_bib49","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1073\/pnas.1513803112","article-title":"High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core pro- tein","volume":"112","author":"Klumppa","year":"2015","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.cld.2021.07.001_bib50","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/S0168-8278(16)00175-6","article-title":"NVR 3\u2013778, a first-in-class HBV core inhibitor, alone and in combination with peg-interferon (PegIFN), in treatment-naive HBeAg-positive patients: early reductions in HBV DNA and HBeAg (abstract)","volume":"64","author":"Yuen","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib51","doi-asserted-by":"crossref","first-page":"S878","DOI":"10.1016\/S0168-8278(20)32197-8","article-title":"Efficacy and safety of GLS4\/ritonavir combined with entecavir in HBeAg-positive patients with chronic hepatitis B: interim results from phase 2b, multi-center study","volume":"73","author":"Zhang","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib52","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0168-8278(20)30773-X","article-title":"Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: interim week 24 data","volume":"73","author":"Janssen","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib53","doi-asserted-by":"crossref","first-page":"e01463-20","DOI":"10.1128\/AAC.01463-20","article-title":"Preclinical profile and characterization of the Hepatitis B virus core protein inhibitor ABI-H0731","volume":"64","author":"Huang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2021.07.001_bib54","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S0618-8278(19)30230-0","article-title":"Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI H0731 with Nuc therapy in treatment naive and treatment suppressed chronic hepatitis B patients","volume":"70","author":"Xiaoli","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib55","first-page":"S736","article-title":"Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection","volume":"75","author":"Gane","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib56","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11095-007-9504-0","article-title":"RNAi for treating hepatitis B viral infection","volume":"25","author":"Chen","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.cld.2021.07.001_bib57","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14712598.2018.1472231","article-title":"siRNA drug development against hepatitis B virus infection","volume":"18","author":"Flisiak","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cld.2021.07.001_bib58","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/S0168-8278(16)00606-1","article-title":"Differential reductions in viral antigens expressed from cccDNA vs integrated DNA in treatment na\u00efve HBeAg positive and negative patients with chronic HBV after RNA interfer- ence therapy with ARC-520","volume":"64","author":"Yuen","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib59","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S0618-8278(19)30092-1","article-title":"Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAG <100 IU\/ml threshold","volume":"70","author":"Yuen","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib60","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0168-8278(20)30597-3","article-title":"Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment","volume":"73","author":"Gane","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib61","first-page":"S287","article-title":"Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results","volume":"75","author":"Gane","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib62","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0168-8278(20)30646-2","article-title":"Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with ISIS 505358 in chronic hepatitis B (CHB) patients on stable nucleos (t)ide analogue (NA) regimen and inNA -naive CHB patients: phase 2a, randomized, double-blind, placebo-controlled study","volume":"73","author":"Yuen","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib63","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: first approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.cld.2021.07.001_bib64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2021.07.001_bib65","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/S0168-8278(15)30133-1","article-title":"Serum HBV-RNA levels decline significantly in chronic hepatitis B patients dosed with the nucleic-acid polymer REP 2139-CA","volume":"62","author":"Jansen","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib66","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.1016\/S0168-8278(16)00590-0","article-title":"Achievement of surface antigen clearance in the liver by combination therapy with REP2139-CA and nucleoside analogues against chronic hepatitis B","volume":"64","author":"Quinet","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib67","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","article-title":"REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV Infection","volume":"5","author":"Vaillant","year":"2019","journal-title":"ACS Infect Dis"},{"issue":"6","key":"10.1016\/j.cld.2021.07.001_bib68","doi-asserted-by":"crossref","first-page":"e0156667","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of Nucleic Acid Polymers in monotherapy and combined with immunotherapy in treatment-naive bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2021.07.001_bib69","first-page":"215","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat Rev"},{"key":"10.1016\/j.cld.2021.07.001_bib70","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepati- tis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2021.07.001_bib71","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib72","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib73","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jvh.12942","article-title":"Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment","volume":"25","author":"Agarwal","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2021.07.001_bib74","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.0c00100","article-title":"Discovery of GS-9688 (Selgantolimod) as a potent and selective oral Toll-Like Receptor 8 agonist for the treatment of chronic hepatitis B","volume":"63","author":"Mackman","year":"2020","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cld.2021.07.001_bib75","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30650-4","article-title":"Efficacy and safety of 24\u00a0weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study","volume":"73","author":"Gane","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib76","first-page":"S757","article-title":"Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B","volume":"75","author":"Janssen1","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib77","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","article-title":"Therapeutic vaccination of chronic hepatitis B patients with virus suppression by anti- viral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine","volume":"25","author":"Vandepapeliere","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.cld.2021.07.001_bib78","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","article-title":"Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific thera- peutic vaccine, in healthy subjects: a randomized study","volume":"32","author":"Gaggar","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cld.2021.07.001_bib79","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and Tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2021.07.001_bib81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5005\/jp-journals-10018-1279","article-title":"Five-year follow-up of chronic Hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac","volume":"8","author":"Aguilar","year":"2018","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.cld.2021.07.001_bib82","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0168-8278(17)30463-4","article-title":"Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir","volume":"66","author":"Wedemeyer","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib83","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2021.07.001_bib84","first-page":"1489A","article-title":"First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA)","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2021.07.001_bib85","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/cpdd.670","article-title":"A\u00a0randomized, double-Blind, placebo-controlled, first-time-in-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects","volume":"8","author":"Han","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cld.2021.07.001_bib86","first-page":"S762","article-title":"A\u00a0single dose of the GalNAc-siRNA, AB-729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos (t)ide analogue therapy in HBeAg negative subjects with chronic hepatitis B infection","volume":"75","author":"Gane","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib87","doi-asserted-by":"crossref","first-page":"e0217433","DOI":"10.1371\/journal.pone.0217433","article-title":"The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice","volume":"14","author":"Gallay","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2021.07.001_bib88","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in\u00a0vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cld.2021.07.001_bib89","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2021.07.001_bib90","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A\u00a0global scientific strategy to cure hepatitis B.","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:58:31Z","timestamp":1761069511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326121000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1089326121000659"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2021.07.001","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapies That May Cure Chronic Hepatitis B Virus","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2021.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}